Protagenic Therapeutics, Inc.new

Over the last 90 days, Protagenic Therapeutics (PTIX) has filed no red-flag 8-Ks related to bankruptcy, delisting, restatement, or officer departures, and no cyber incidents have been detected in our ingestion pipeline. However, absence of signal in a 90-day window does not indicate absence of risk; the full 12-month historical record often reveals material events and patterns that shorter windows miss. The full $49 Report adds dilution risk scoring, comprehensive 8-K context, financing history analysis, and AI-driven risk signals across governance, liquidity, and regulatory exposure. It provides the longitudinal view necessary to assess whether PTIX's recent quiet period reflects operational stability or merely the gap between filing events.